Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | USP28 | Q96RU2 | 7/20 | 0.39 |
| ▸ | USP25 | Q9UHP3 | 4/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064390 | 0.85 | SCN9A (0.43) | USP28USP25SCN9AHPGDSPARP1 | |
| SCHEMBL29085170 | 0.85 | SCN9A (0.43) | USP28USP25SCN9AHPGDSPARP1 | |
| SCHEMBL29085174 | 0.85 | SCN9A (0.43) | USP28USP25SCN9AHPGDSPARP1 | |
| SCHEMBL29085217 | 0.83 | ALDH1A1 (0.39) | BACE1USP28USP25PARP1 | |
| SCHEMBL25235207 | 0.83 | PARP1 (0.45) | USP28USP25HPGDSPARP1 | |
| SCHEMBL30273150 | 0.83 | PARP1 (0.45) | USP28USP25HPGDSPARP1 | |
| SCHEMBL31514765 | 0.82 | PARP1 (0.43) | BACE1SCN9AHPGDSPARP1 | |
| Hydrochloric Acid SCHEMBL31552839 | 0.82 | PARP1 (0.44) | USP28USP25HPGDSPARP1 | |
| SCHEMBL29085237 | 0.81 | TYK2 (0.39) | BACE1USP28USP25SCN9APARP1 | |
| SCHEMBL30064539 | 0.79 | SCN9A (0.42) | USP28USP25SCN9AHPGDSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024050370-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | BACE1 1468/4885HRH4 3356/4885USP28 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.